Holen Sie sich die Stockscreener-App
2.93
3.53%
0.10
Handel nachbörslich:
2.88
-0.05
-1.71%
Schlusskurs vom Vortag:
$2.83
Offen:
$2.83
24-Stunden-Volumen:
310.92K
Relative Volume:
1.14
Marktkapitalisierung:
$298.20M
Einnahmen:
$4.60M
Nettoeinkommen (Verlust:
$-82.31M
KGV:
-3.5723
EPS:
-0.8202
Netto-Cashflow:
$-87.79M
1W Leistung:
+3.90%
1M Leistung:
+3.17%
6M Leistung:
+0.00%
1J Leistung:
+73.37%
1-Tages-Spanne:
$2.82
$3.03
1-Wochen-Bereich:
$2.75
$3.03
52-Wochen-Spanne:
$1.60
$4.00
Ac Immune Sa Stock (ACIU) Company Profile
Compare ACIU vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ACIU
Ac Immune Sa
|
2.93 | 288.02M | 4.60M | -82.31M | -87.79M | -0.8202 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ac Immune Sa Stock (ACIU) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-31 | Eingeleitet | BTIG Research | Buy |
| 2019-02-01 | Herabstufung | UBS | Buy → Neutral |
| 2019-01-04 | Eingeleitet | UBS | Buy |
| 2018-04-05 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-03-23 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2016-10-18 | Eingeleitet | Credit Suisse | Outperform |
| 2016-10-18 | Eingeleitet | Jefferies | Buy |
| 2016-10-18 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Ac Immune Sa Aktie (ACIU) Neueste Nachrichten
AC Immune (ACIU) Reveals Promising Data on ALS PET Tracer - GuruFocus
AC Immune presents new Phase 1 data on uptake of ACI-19626 - TipRanks
AC Immune Announces Phase 1 Results Showing Enhanced Uptake of TDP-43 PET Tracer ACI-19626 in ALS Patients at 2026 TDP43 Summit - Quiver Quantitative
AC Immune’s PET tracer shows uptake in ALS patients’ brains - Investing.com
AC Immune's experimental ALS brain scan visualizes TDP-43 buildup - Stock Titan
AC Immune Q1 2026 Earnings: Narrowed Loss Beats Estimates as Pipeline Progress ContinuesCommunity Hot Stocks - Newser
Top Executive Move at AC Immune SA Sparks Fresh Investor Buzz - TipRanks
10K-share sale by AC Immune (ACIU) CEO Andrea Pfeifer disclosed - Stock Titan
Co-founder and CEO steps down - European Biotechnology Magazine
Affiliate sells 20,000 shares — ACIU (NASDAQ: ACIU) reports Form 144 - Stock Titan
AC Immune Sets June AGM and Reshapes Leadership as Long-Serving CEO Retires - TipRanks
Leadership shift at AC Immune (NASDAQ: ACIU) as AGM sets pay and capital votes - Stock Titan
AC Immune SA Announces Retirement of Andrea Pfeifer as CEO - marketscreener.com
AC Immune (ACIU) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance
AC Immune announces the unexpected departure of its co-founder and CEO - Agefi.com
AC Immune CEO and Co-Founder Andrea Pfeifer to Retire at June 11 AGM; Board Chair Martin Zügel Named Interim Chief - TipRanks
AC Immune (ACIU) founder-CEO Andrea Pfeifer to retire; board chair named interim CEO - Stock Titan
AC Immune CEO Andrea Pfeifer to retire after 23 years - Investing.com
AC Immune CEO Andrea Pfeifer to retire after 23 years By Investing.com - Investing.com Australia
AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM - The Manila Times
AC Immune SA (ACIU) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Why AC Immune (ACIU) ability to generate cash matters (-1.33%) 2026-05-06Buy Zone Stocks - newser.com
ACIU Reiterated by BTIG -- Price Target Maintained at $8.00 - GuruFocus
MSN Money - MSN
AC Immune Releases Q1 2026 Financial Results - AlphaStreet
ACIU Reports Strong Q1 Revenue Growth and Advances Neurodegenera - GuruFocus
AC Immune reports Q1 EPS (15c), consensus (14c) - TipRanks
AC Immune Posts Q1 2026 Update, Extends Cash Runway and Advances Neurodegeneration Pipeline - TipRanks
AC Immune doses first patient in final ABATE trial cohort By Investing.com - Investing.com South Africa
AC Immune doses first patient in final ABATE trial cohort - Investing.com
AC Immune First Quarter 2026 Financial and Corporate Updates - The Manila Times
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease - The Manila Times
AC Immune: Q1 Earnings Snapshot - Barchart.com
AC Immune (NASDAQ: ACIU) trims Q1 2026 loss, sees cash runway into Q4 2027 - Stock Titan
AC Immune (NASDAQ: ACIU) triggers $12M Takeda milestone with final ABATE cohort - Stock Titan
AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 - GlobeNewswire
AC Immune SA (HAM:IMR) Dividend - GuruFocus
AC Immune SA (HAM:IMR) Stock Price & 30 Year Financial Data - GuruFocus
Who's Buying or Selling AC Immune SA (HAM:IMR) Stock Today? - GuruFocus
AC Immune SA Stock Baskets - GuruFocus
AC Immune Stock Operating Data - GuruFocus
AC Immune SA (HAM:IMR) Stock Earnings Transcripts - GuruFocus
AC Immune SA (HAM:IMR) Stock Price, Trades & News - GuruFocus
AC Immune SA (HAM:IMR) Stock News, Headlines & Updates - GuruFocus
AC Immune SA (HAM:IMR) Stock HoldersInstitutional & Insider Ownership - GuruFocus
AC Immune SA (HAM:IMR) Competitors 2026 - GuruFocus
AC Immune SA (HAM:IMR)Valuation Measures & Financial Statistics - GuruFocus
ACIU stock rallies 16.3% in a week: Here's what you need to know - MSN
What interest rate risk AC Immune (ACIU)? (Investors Pile In) 2026-04-27Hedge Fund Favorites - newser.com
ACIU.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
ACIU.O Technical Analysis & Stock Price Forecast - Intellectia AI
Finanzdaten der Ac Immune Sa-Aktie (ACIU)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):